Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shanghai - Delayed Quote CNY

Guizhou Yibai Pharmaceutical Co., Ltd. (600594.SS)

Compare
3.5700
+0.0200
+(0.56%)
At close: April 3 at 3:00:04 PM GMT+8
Loading Chart for 600594.SS
  • Previous Close 3.5500
  • Open 3.5100
  • Bid 3.5700 x --
  • Ask 3.5800 x --
  • Day's Range 3.5100 - 3.6300
  • 52 Week Range 2.7600 - 4.9200
  • Volume 12,481,600
  • Avg. Volume 10,618,976
  • Market Cap (intraday) 2.827B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3000
  • Earnings Date --
  • Forward Dividend & Yield 0.07 (1.85%)
  • Ex-Dividend Date Jun 7, 2024
  • 1y Target Est --

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.

www.gzcci.com

5,509

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600594.SS

View More

Performance Overview: 600594.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600594.SS
0.28%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

600594.SS
25.73%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

600594.SS
50.98%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

600594.SS
16.85%
SSE Composite Index (000001.SS)
20.91%

Compare To: 600594.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600594.SS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    2.83B

  • Enterprise Value

    3.07B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.18

  • Price/Book (mrq)

    1.07

  • Enterprise Value/Revenue

    1.28

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -9.83%

  • Return on Assets (ttm)

    -2.28%

  • Return on Equity (ttm)

    -7.98%

  • Revenue (ttm)

    2.4B

  • Net Income Avi to Common (ttm)

    -235.62M

  • Diluted EPS (ttm)

    -0.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    619.88M

  • Total Debt/Equity (mrq)

    31.14%

  • Levered Free Cash Flow (ttm)

    241.08M

Research Analysis: 600594.SS

View More

Company Insights: 600594.SS

Research Reports: 600594.SS

View More

People Also Watch